Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Difference in the Incidences of the Most Prevalent Urologic Cancers from 2003 to 2009 in Iran

  • Basiri, Abbas (Department of Urology, Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences) ;
  • Shakhssalim, Nasser (Department of Urology, Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences) ;
  • Jalaly, Niloofar Yahyapour (Department of Urology, Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences) ;
  • Miri, Hamid Heidarian (Department of Epidemiology, Shiraz University of Medical Sciences) ;
  • Partovipour, Elham (Cancer Office, Non Communicable Disease Unit, Ministry of Health and Medical Education) ;
  • Panahi, Mohammad Hossein (Cancer Office, Non Communicable Disease Unit, Ministry of Health and Medical Education)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Urological cancers represent a major public problem associated with high mortality and morbidity. The pattern of these cancers varies markedly according to era, region and ethnic groups, but increasing incidence trends overall makes focused epidemiological studies important. The aim of the present study was to assess the incidence of most prevalent urological cancers in Iran from 2003 to 2009. Materials and Methods: The data for this study were obtained from the population-based Cancer Registry Center of the Iran Ministry of Health and Medical Education. Differences of mean age and age distributions of each cancer were compared between 2003 and 2009 in men and women. Results: Bladder cancer was the most common urologic cancer in both genders. The rate difference of age standardized ratio (ASR) of bladder and renal cell carcinoma in women were 1.54 and 2.01 percent per 100,000 population from 2003 to the 2009, respectively. In men, the rate difference of age standardized ratio of prostate, testis, kidney and bladder cancer was also 2.23, 1.2, 1.8 and 1.5 percent per 100,000 population from 2003 to 2009, respectively. The mean ages of patients in all cancers in both genders did not differ significantly through time (p value>0.05) but the distribution of ages of patients with bladder and prostate cancer changed significantly from 2003 to 2009 (p value<0.001). Conclusions: The results of present study suggest the general pattern and incidence of urological cancers in Iran are changing, the observed increase pointing to a need for urological cancer screening programs.

Keywords

References

  1. Akbari ME, Hosseini SJ, Rezaee A, et al (2008). Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev, 9, 549-52.
  2. Basile S, Angioli R, Manci N, et al (2006). Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. Int J Gynecol Cancer, 16, 1491-7. https://doi.org/10.1111/j.1525-1438.2006.00619.x
  3. Bedwani R, El-Khwsky F, La Vecchia C, et al (1993). Descriptive epidemiology of bladder cancer in Egypt. Int J Cancer, 55, 351-2. https://doi.org/10.1002/ijc.2910550228
  4. Bray F, Lortet-Tieulent J, Ferlay J, et al (2010). Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer, 46, 3040-52. https://doi.org/10.1016/j.ejca.2010.09.013
  5. Bray F, Richiardi L, Ekbom A, et al (2006). Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer, 118, 3099-111. https://doi.org/10.1002/ijc.21747
  6. Brennan P, van der Hel O, Moore LE, et al (2008). Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br J Cancer, 99, 1912-5. https://doi.org/10.1038/sj.bjc.6604761
  7. Cheon J, Kim CS, Lee ES, et al (2002). Survey of incidence of urological cancer in South Korea: a 15-year summary. Int J Urol, 9, 445-54. https://doi.org/10.1046/j.1442-2042.2002.00500.x
  8. Chu KC, Tarone RE, Freeman HP (2003). Trends in prostate cancer mortality among black men and white men in the United States. Cancer, 97, 1507-16. https://doi.org/10.1002/cncr.11212
  9. Cohen HT, McGovern FJ (2005). Renal-cell carcinoma. N Engl J Med, 353, 2477-90. https://doi.org/10.1056/NEJMra043172
  10. Dieckmann KP, Pichlmeier U (2004). Clinical epidemiology of testicular germ cell tumors. World J Urol, 22, 2-14. https://doi.org/10.1007/s00345-004-0398-8
  11. Duncan ME, Goldacre MJ (2011). Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979-2006. BJU Int, 107, 40-5. https://doi.org/10.1111/j.1464-410X.2010.09487.x
  12. Edwards BK, Ward E, Kohler BA, et al (2010). Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 116, 544-73. https://doi.org/10.1002/cncr.24760
  13. Gallus S, Colombo P, Scarpino V, et al (2006). Overweight and obesity in Italian adults 2004, and an overview of trends since 1983. Eur J Clin Nutr, 60, 1174-9. https://doi.org/10.1038/sj.ejcn.1602433
  14. Gondos A, Bray F, Hakulinen T, et al (2009). Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol, 20, 564-73.
  15. Ildaphonse G, George PS, Mathew A (2009). Obesity and kidney cancer risk in men: a meta-analysis (1992-2008). Asian Pac J Cancer Prev, 10, 279-86.
  16. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30. https://doi.org/10.3322/canjclin.56.2.106
  17. Karim-Kos HE, de Vries E, Soerjomataram I, et al (2008). Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer, 44, 1345-89. https://doi.org/10.1016/j.ejca.2007.12.015
  18. Levi F, Lucchini F, Negri E, et al (2004). Leveling of prostate cancer mortality in Western Europe. Prostate, 60, 46-52. https://doi.org/10.1002/pros.20058
  19. Long XJ, Lin S, Sun YN, Zheng ZF (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis." Asian Pac J Cancer Prev, 13, 4097-100. https://doi.org/10.7314/APJCP.2012.13.8.4097
  20. Mathew A, George PS, Ildaphonse G (2009). Obesity and kidney cancer risk in women: a meta-analysis (1992-2008). Asian Pac J Cancer Prev, 10, 471-8.
  21. McDavid K, Lee J, Fulton JP, et al (2004). Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep, 119, 174-86.
  22. McGlynn KA, Cook MB (2009). Etiologic factors in testicular germ-cell tumors. Future Oncol, 5, 1389-402. https://doi.org/10.2217/fon.09.116
  23. McGlynn KA, Devesa SS, Sigurdson AJ, et al (2003). Trends in the incidence of testicular germ cell tumors in the United States. Cancer, 97, 63-70. https://doi.org/10.1002/cncr.11054
  24. Ministry of Health and Organization (2006). Guideline: National Cancer Registry. Tehran.
  25. Moller H, Skakkebaek NE (1996). Risks of testicular cancer and cryptorchidism in relation to socio-economic status and related factors: case-control studies in Denmark. Int J Cancer, 66, 287-93. https://doi.org/10.1002/(SICI)1097-0215(19960503)66:3<287::AID-IJC2>3.0.CO;2-V
  26. Moller H, Skakkebaek NE (1997). Testicular cancer and cryptorchidism in relation to prenatal factors: case-control studies in Denmark. Cancer Causes Control, 8, 904-12. https://doi.org/10.1023/A:1018472530653
  27. Moore MA, Eser S, Igisinov N, et al (2010). Cancer epidemiology and control in North-Western and Central Asia - past, present and future. Asian Pac J Cancer Prev, 11, 17-32.
  28. Morrison AS, Buring JE,Verhoek WG, et al (1984). An international study of smoking and bladder cancer. J Urol, 131, 650-4.
  29. Panagiotopoulou K, Katsouyanni K, Petridou E, et al (1990). Maternal age, parity, and pregnancy estrogens. Cancer Causes Control, 1, 119-24. https://doi.org/10.1007/BF00053162
  30. Parker SL, Tong T, Bolden S, et al (1997). Cancer statistics, 1997. CA Cancer J Clin, 47, 5-27. https://doi.org/10.3322/canjclin.47.1.5
  31. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  32. Purdue MP, Devesa SS, Sigurdson AJ, et al (2005). International patterns and trends in testis cancer incidence. Int J Cancer 115, 822-7. https://doi.org/10.1002/ijc.20931
  33. Qin Q, Xu X, Wang X, et al (2013). Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev, 14, 3117-21. https://doi.org/10.7314/APJCP.2013.14.5.3117
  34. Rohani-Rasaf M, Abdollahi M, Jazayeri S, et al (2013). Correlation of cancer incidence with diet, smoking and socio- economic position across 22 districts of Tehran in 2008. Asian Pac J Cancer Prev, 14, 1669-76. https://doi.org/10.7314/APJCP.2013.14.3.1669
  35. Safe S (2002). Environmental estrogens: roles in male reproductive tract problems and in breast cancer. Rev Environ Health, 17, 253-62.
  36. Shahar S, Shafurah S, Hasan Shaari NS, et al (2011). Roles of diet, lifetime physical activity and oxidative DNA damage in the occurrence of prostate cancer among men in Klang Valley, Malaysia. Asian Pac J Cancer Prev, 12, 605-11.
  37. Shakhssalim N, Hosseini SY, Basiri A, et al (2010). Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev, 11, 601-6.
  38. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  39. World Health Organization (2000). International Classification of diseases for oncology: ICD-O. London.
  40. Yang XQ, Xu C, Sun Y, Han RF (2013). Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac J Cancer Prev, 14, 2583-9. https://doi.org/10.7314/APJCP.2013.14.4.2583
  41. Yavari P, Sadrolhefazi B, Mohagheghi MA, et al (2009). A descriptive retrospective study of bladder cancer at a hospital in Iran (1973-2003). Asian Pac J Cancer Prev, 10, 681-4.

Cited by

  1. Histopathologic Characterization of Prostate Diseases in Madinah, Saudi Arabia vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4175
  2. Demographic Survey of Four Thousand Patients with 10 Common Cancers in North Eastern Iran over the Past Three Decades vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10193
  3. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy - Iranian Experience vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5043
  4. Epidemiology and Trends in Incidence of Kidney Cancer in Iran vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5859
  5. Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3241
  6. Distribution of Testicular Tumors in Lebanon: A Single Institution Overview vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3443
  7. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.839
  8. Predictive Effect of Preoperative Anemia on Long-Term Survival Outcomes with Non-Muscle Invasive Bladder Cancer vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1755
  9. The role of blood neutrophil count and the neutrophil-to-lymphocyte ratio as a predictive factor for prostate biopsy results pp.1724-6075, 2018, https://doi.org/10.1177/0391560318766822
  10. The incidence of kidney cancer in Iran: a systematic review and meta-analysis vol.8, pp.2, 2018, https://doi.org/10.1051/bmdcn/2018080209